var data={"title":"Investigational and ineffective therapies for sepsis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Investigational and ineffective therapies for sepsis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/contributors\" class=\"contributor contributor_credentials\">Gregory A Schmidt, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/contributors\" class=\"contributor contributor_credentials\">Peter F Clardy, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/contributors\" class=\"contributor contributor_credentials\">Polly E Parsons, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 19, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of potential therapies have been investigated or are being evaluated in an attempt to improve clinical outcomes in sepsis. Therapies that are being investigated are the focus of this review, although none are recommended for use at this time because the ratio of potential benefits and harms has not been adequately studied. Therapies that have proven ineffective are also mentioned briefly. The definition, pathophysiology, and management of sepsis are discussed elsewhere. (See <a href=\"topic.htm?path=sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis\" class=\"medical medical_review\">&quot;Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis&quot;</a> and <a href=\"topic.htm?path=evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults\" class=\"medical medical_review\">&quot;Evaluation and management of suspected sepsis and septic shock in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2552507\"><span class=\"h1\">THERAPIES BEING INVESTIGATED</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of potential therapies for sepsis appear promising in animal models, but have not yet been adequately studied in humans. Other potential therapies have been studied in humans, but have given conflicting results and require additional investigations to clarify their effects. These therapies are the focus of this section. Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a href=\"http://www.clinicaltrials.gov/&amp;token=NK91I08KOJ1eJ1hT1o/oHgJu4vbbEBRl2V0d48fIIMDpbZTpeZvuNaOE2M5VxYDS&amp;TOPIC_ID=1631\" target=\"_blank\" class=\"external\">www.clinicaltrials.gov</a>).</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Inhibition of innate immunity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infecting microbes display highly conserved macromolecules (eg, lipopolysaccharides, peptidoglycans) on their surface. When these macromolecules are recognized by pattern-recognition receptors (called Toll-like receptors [TLRs]) on the surface of immune cells, the host&rsquo;s immune response is initiated. This may contribute to the excess systemic inflammatory response that characterizes sepsis. Inhibition of several TLRs is being evaluated as a potential therapy for sepsis:</p><p>Inhibition of TLR-4 with the antagonist, E5564 (Eritoran) was tested in humans with severe sepsis in the ACCESS (<strong>A</strong> <strong>C</strong>ontrolled <strong>C</strong>omparison of <strong>E</strong>ritoran Tetrasodium and Placebo in Patients with <strong>S</strong>evere <strong>S</strong>epsis) Trial, showing no effect on 28-day mortality [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/1\" class=\"abstract_t\">1</a>]. An earlier clinical trial that evaluated the inhibition of TLR-4 with another antagonist, TAK 242 (Resatorvid), found a non-statistically significant reduction in 28-day mortality [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/2\" class=\"abstract_t\">2</a>]. </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Intravenous immune globulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It has been hypothesized that polyclonal intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) may benefit patients with sepsis by binding endotoxin. However, we and others believe that IVIG should NOT be administered to patients with sepsis [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/3-10\" class=\"abstract_t\">3-10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suggesting that polyclonal IVIG has no benefit, a randomized trial of 653 patients with sepsis found that IVIG did not reduce 28-day mortality compared to placebo [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suggesting that polyclonal IVIG has a benefit, meta-analyses of randomized trials found that polyclonal IVIG decreased mortality compared to either placebo or no IVIG [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/4-7\" class=\"abstract_t\">4-7</a>]. The mortality benefit was greatest when IgA- or IgM-enriched IVIG was used [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/6,7\" class=\"abstract_t\">6,7</a>]. However, all of the meta-analyses were limited by heterogeneity and two of the meta-analyses found that the mortality benefit disappeared when only the well-designed trials were analyzed [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/5,7\" class=\"abstract_t\">5,7</a>].</p><p/><p>Well-designed randomized trials are warranted to evaluate the impact of IgA- and IgM-enriched IVIG [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=overview-of-intravenous-immune-globulin-ivig-therapy\" class=\"medical medical_review\">&quot;Overview of intravenous immune globulin (IVIG) therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Cytokine and endotoxin inactivation or removal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Strategies to improve sepsis by either inactivating or removing endotoxin <span class=\"nowrap\">and/or</span> inflammatory cytokines have been investigated:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemoperfusion through adsorptive materials &ndash; Perfusion of blood from patents with sepsis through adsorptive membranes or sorbent-containing cartridges can remove harmful circulating cytokines and endotoxin. For example, several observational studies and one small randomized trial of patients with sepsis reported that hemoperfusion through a membranous <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">polymyxin B</a> fiber column (PBFC; high affinity for endotoxin) may be beneficial [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/11-14\" class=\"abstract_t\">11-14</a>]. One multicenter trial randomly assigned 64 patients with severe sepsis or septic shock due to surgery-related intraabdominal infection to receive conventional therapy alone or conventional therapy plus PBFC hemoperfusion [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/14\" class=\"abstract_t\">14</a>]. Use of PBFC was associated with a lower 28-day mortality (32 versus 53 percent; adjusted HR 0.36, 95% CI 0.16-0.80) as well as a higher mean arterial pressure and decreased vasopressor requirement at 72 hours. In contrast, one retrospective study of 642 patients with abdominal septic shock reported no survival benefit with polymyxin B hemoperfusion compared to historical controls [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\">Hemoperfusion through sorbent-containing cartridges (hemadsorption) provides a larger surface area than membranous columns to enhance the removal of cytokines and inflammatory molecules involved in the pathogenesis of sepsis. Among the existing sorbents, CytoSorb (porous polymer beads) appears to be the most promising in animal models with limited data in humans [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/16-19\" class=\"abstract_t\">16-19</a>]. However, it does not remove the two more potent inflammatory molecules, endotoxin and interleukin-10. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plasma or whole blood exchange &ndash; Case series and observational studies with historical controls reported favorable outcomes when endotoxin was removed by plasma or whole blood exchange, including lower plasma endotoxin concentrations and, possibly, lower mortality [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/20-22\" class=\"abstract_t\">20-22</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coupled plasma filtration adsorption (CPFA) &ndash; CFPA combines the separation of plasma from the cellular components of blood with a highly permeable filter (plasma filter) followed by sorbent adsorption of the plasma component with a styrene resin. In one multicenter trial of 330 adult patients with septic shock, compared to conventional care, CPFA was not associated with a mortality benefit (45 versus 47 percent) nor did it prevent the development of new organ failures or decrease length of ICU stay [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interleukin-1 is a pro-inflammatory cytokine implicated in sepsis-related multiorgan dysfunction syndrome. Anakinra (a recombinant, non-glycosylated human interleukin-1 receptor antagonist) failed to improve survival in two clinical trials enrolling subjects with severe sepsis and septic shock [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Recent reports that anakinra is effective for patients with macrophage activation syndrome have rekindled interest in identifying subsets of severe sepsis in which the drug may be useful. When data from the original confirmatory phase III trial [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/24\" class=\"abstract_t\">24</a>] were reanalyzed, grouping subjects according to the presence of hepatobiliary dysfunction and disseminated intravascular coagulation (as markers for macrophage activation), treatment with anakinra was associated with improved survival in those with macrophage activation, but not in those without [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/26\" class=\"abstract_t\">26</a>]. The patients who met criteria for macrophage activation was a small subset of the overall group, so this finding (if confirmed) may pertain to few patients with septic shock.</p><p/><p>While some of these therapies are promising, we believe that additional evidence from large randomized trials are necessary before any of these strategies can be routinely used in patients with sepsis. </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Interferon-gamma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A decrease in monocyte function has been observed late in the course of sepsis, which may predispose patients to life-threatening secondary infections. This observation prompted a study in which patients with sepsis were administered interferon-gamma [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/27\" class=\"abstract_t\">27</a>]. The study found that interferon-gamma restored monocytic cell function. Controlled clinical trials measuring patient-important outcomes in patients with sepsis have not been reported, although a trial evaluating the impact of interferon-gamma in candidemia is underway [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/28\" class=\"abstract_t\">28</a>]. </p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Granulocyte-macrophage colony stimulating factor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Granulocyte-macrophage colony stimulating factor (GM-CSF, <a href=\"topic.htm?path=sargramostim-drug-information\" class=\"drug drug_general\">sargramostim</a>, molgramostim) is a cytokine that promotes maturation of the progenitor cells of granulocytes, erythrocytes, megakaryocytes, and macrophages, as well as mature neutrophils, monocytes, macrophages, dendritic cells, T-lymphocytes, and plasma cells. Its use in sepsis has been studied in several controlled clinical trials.</p><p>One trial reported that GM-CSF increased the peripheral neutrophil count, but did not affect the mortality, duration of ICU stay, or rate of hospital discharge [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/29\" class=\"abstract_t\">29</a>]. Another trial found that GM-CSF reduced the rate of infectious complications, the length of hospital stay, and the duration of antibiotic therapy, without affecting mortality [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/30\" class=\"abstract_t\">30</a>]. And, a third trial found that GM-CSF induced a trend toward a shorter duration of mechanical ventilation (148 versus 207 hours), a shorter hospital stay (59 versus 69 days), and a shorter ICU stay (41 versus 52 days) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/31\" class=\"abstract_t\">31</a>]. All of the trials were small with few events, which is the reason why large absolute differences were often not statistically significant. We believe that larger controlled clinical trials are necessary to confirm the clinical effects reported in these trials and that GM-CSF should not be routinely used to treat sepsis until then.</p><p>The effects of granulocyte colony stimulating factor (G-CSF) are mentioned below. (See <a href=\"#H2552815\" class=\"local\">'Ineffective therapies'</a> below.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Augmentation of immunomodulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antibodies directed against macrophage migration inhibition factor (MIF) prevented death in a study that used a cecal puncture animal model of sepsis, even when administered up to eight hours after the onset of peritonitis [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/32\" class=\"abstract_t\">32</a>]. The mechanism of action is uncertain, but MIF inhibition might restore or augment the immunomodulatory actions of endogenous glucocorticoids [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/33\" class=\"abstract_t\">33</a>]. While it is known that elevated MIF levels correlate with poor outcomes in humans with sepsis [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/33,34\" class=\"abstract_t\">33,34</a>], the impact of MIF inhibition has not been studied in humans.</p><p class=\"headingAnchor\" id=\"H2553632\"><span class=\"h2\">Inhibition of proinflammatory gene expression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A synthetic peptide has been developed that inhibits bacterial superantigen-induced expression of certain proinflammatory genes (interleukin-2, gamma interferon, and tumor necrosis factor-beta) by limiting T-cell activation. In one study, the peptide protected mice against lethal challenges with staphylococcal and streptococcal superantigen, when administered up to three hours after the superantigen [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/35\" class=\"abstract_t\">35</a>]. This peptide has not been tested in humans.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Hemofiltration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It has been proposed that hemofiltration, as a mode of dialysis, may remove proinflammatory molecules that induce hemodynamic collapse in septic shock, thereby improving outcomes. However, data from small randomized trials of hemofiltration (high volume or continuous) in patients with septic shock suggest that there is insufficient evidence for the routine use of this mode of renal replacement therapy over conventional hemodialysis.</p><p>Initial studies suggested that the high volume hemofiltration offered benefit over conventional hemodialysis for the treatment of acute renal failure in sepsis [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/36-39\" class=\"abstract_t\">36-39</a>]. However, meta-analyses of small randomized studies and one multicenter prospective study (IVOIRE) suggested no benefit [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/40,41\" class=\"abstract_t\">40,41</a>]. </p><p>Similarly, a randomized trial that evaluated continuous venovenous hemofiltration (CVVH) in patients with sepsis did not demonstrate any improvement in the clearance of inflammatory mediators or clinical outcomes [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/42\" class=\"abstract_t\">42</a>]. Another trial was discontinued after an interim analysis showed more frequent and more severe organ failure in the hemofiltration group [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Anticoagulants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Heparin has anti-thrombotic and immunomodulating effects, both of which have the potential to be beneficial in sepsis. In a retrospective cohort study of patients with septic shock, intravenous therapeutic heparin was associated with decreased mortality, discontinuation of vasoactive drug infusions, and liberation from mechanical ventilation [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/44\" class=\"abstract_t\">44</a>]. The risk of major hemorrhage or the need for transfusion was not increased. This study was followed by the HETRASE trial, which randomly assigned 319 patients with sepsis to receive low dose intravenous heparin (500 units per hour) or placebo for seven days [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/45\" class=\"abstract_t\">45</a>]. The trial found no improvement in any clinical outcome. It has been suggested that the conflicting results were due to the randomized trial using a low dose of heparin; as a result, a randomized trial comparing various doses of heparin in patients with septic shock is being conducted [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/46\" class=\"abstract_t\">46</a>]. </p><p>The role of recombinant thrombomodulin and antithrombin in sepsis-induced disseminated intravascular coagulation (DIC) are also being investigated and may hold promise [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/47,48\" class=\"abstract_t\">47,48</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Naloxone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A meta-analysis of three randomized trials (61 patients) comparing <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> to either placebo or no naloxone found that naloxone therapy led to hemodynamic improvement, but did not improve the case-fatality rate [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/49\" class=\"abstract_t\">49</a>]. Adverse effects that have been associated with naloxone therapy include pulmonary edema, hypertension, and seizures [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/50\" class=\"abstract_t\">50</a>]. Given the limitations of the meta-analysis that found a physiological benefit, the absence of patient-important benefits, and the potential for adverse effects, we believe that naloxone therapy is not warranted for patients with septic shock. However, large controlled trials are justified, since the studies included in the meta-analysis had too few events to definitively exclude a beneficial effect.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Pentoxifylline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sepsis results in decreased red cell deformability and increased erythrocyte aggregation, effects that may be mitigated by <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">pentoxifylline</a> [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/51\" class=\"abstract_t\">51</a>]. Pentoxifylline also inhibits neutrophil adhesion and activation, and modulates endotoxin-induced expression of proinflammatory cytokines [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/52\" class=\"abstract_t\">52</a>]. In a trial of 51 surgical patients with severe sepsis who were randomly assigned to receive pentoxifylline or placebo, pentoxifylline improved the multiple organ dysfunction score and the arterial oxygen tension to fraction of inspired oxygen (PaO<sub>2</sub><span class=\"nowrap\">/FiO<sub>2</sub>),</span> but there was no improvement in the 28-day mortality [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/53\" class=\"abstract_t\">53</a>]. Additional trials are needed to identify a true beneficial clinically meaningful effect.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Statins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HMG CoA reductase inhibitors (statins) are in wide clinical use and have an established role in the management of hyperlipidemia and cardiovascular disease. Statins also appear to have beneficial antiinflammatory properties, such as suppression of endotoxin-induced up-regulation of TLR-4 and TLR-2. Although early studies of statins in patients with sepsis suggested benefit, most studies since then, including meta-analyses of randomized trials, show no benefit from statin use in this population [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/54-63\" class=\"abstract_t\">54-63</a>]. (See <a href=\"topic.htm?path=statins-possible-noncardiovascular-benefits#H5\" class=\"medical medical_review\">&quot;Statins: Possible noncardiovascular benefits&quot;, section on 'Sepsis and infections'</a> and <a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults#H648483\" class=\"medical medical_review\">&quot;Treatment of hospital-acquired and ventilator-associated pneumonia in adults&quot;, section on 'Lack of benefit of statins'</a>.)</p><p class=\"headingAnchor\" id=\"H79437663\"><span class=\"h2\">Beta-blockade</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beta-blocker therapy may potentially attenuate the deleterious effects of the sympathetic adrenergic response that occurs during septic shock. One open-label, single center trial randomized 154 patients with septic shock to an <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a> infusion or standard therapy [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/64\" class=\"abstract_t\">64</a>]. All patients on esmolol achieved the pre-set target heart rate (HR) of 80 to 94 <span class=\"nowrap\">beats/min</span> without a significant drop in mean arterial pressure (median dose 100 <span class=\"nowrap\">mg/hour)</span>. Compared to patients on standard therapy, patients receiving esmolol had improvements in the following variables at 96 hours:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Greater decline from baseline HR (by 28 <span class=\"nowrap\">beats/min</span> versus 6 <span class=\"nowrap\">beats/min)</span> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Higher left ventricular stroke work index (43 versus 31 <span class=\"nowrap\">mL/m<sup>2</sup>)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced need for vasopressors (-0.11 <span class=\"nowrap\">mcg/kg/min</span> versus -0.01 <span class=\"nowrap\">mcg/kg/min)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced need for fluid replacement therapy <span class=\"nowrap\">(4L/day</span> versus 5.4 <span class=\"nowrap\">L/day)</span> </p><p/><p>Improvements were also observed in secondary outcomes that included metabolic variables (eg, lactate and pH), markers of end organ function (eg, glomerular filtration rate) and 28-day mortality (50 versus 81 percent). Further validation of these findings is warranted before <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a> can be routinely recommended as a therapy in patients with septic shock.</p><p class=\"headingAnchor\" id=\"H3996667372\"><span class=\"h2\">Vitamin C, thiamine, and hydrocortisone combination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of vitamin C, thiamine, and <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> may benefit patients with sepsis. Hydrocortisone and vitamin C act synergistically on the inflammatory cascade. Vitamin C is also an antioxidant. Thiamine (vitamin B1) prevents renal oxalate crystallization when vitamin C is administered in high doses. One retrospective single institution study of 47 patients with sepsis or septic shock and a procalcitonin level &gt;2 <span class=\"nowrap\">ng/mL,</span> examined the effects of high-dose intravenous (IV) vitamin C (1.5 g every six hours for four days or until ICU discharge), IV thiamine (200 mg every 12 hours for four days or until ICU discharge), and IV hydrocortisone (50 mg every six hours for seven days or until ICU discharge) given early during the course of sepsis (ie, within the first 24 hours of intensive care [ICU] admission) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/65\" class=\"abstract_t\">65</a>]. Compared with 47 historical controls who were treated in an era prior to the institution of the vitamin C protocol, the vitamin C regimen was associated with reduced in-hospital mortality (8.5 versus 40.4 percent), more rapid weaning of vasopressors (18 versus 55 hours), and the prevention of progressive organ dysfunction. While encouraging, methodologic flaws including retrospective nature, inclusion of nonconsecutive cases, propensity analysis suggest that randomized trials are required before a vitamin C protocol can be used routinely.</p><p class=\"headingAnchor\" id=\"H2552815\"><span class=\"h1\">INEFFECTIVE THERAPIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of potential therapies for sepsis have been investigated, but either caused harm or failed to improve clinical outcomes.</p><p>Despite promising initial data, recombinant human activated protein C (rhAPC) has not been confirmed to improve survival in patients with severe sepsis or septic shock, prompting withdrawal of this drug from the market [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/66\" class=\"abstract_t\">66</a>]. Recombinant human activated protein C (also called drotrecogin alfa) promotes fibrinolysis and inhibits thrombosis. It was hypothesized that rhAPC may benefit patients with sepsis because it modulates the procoagulant response that is believed to contribute to multisystem organ dysfunction. This hypothesis was initially tested in the PROWESS trial, which reported that rhAPC improved 28-day mortality in patients with severe sepsis or septic shock, with its greatest benefit among patients with a high risk of death (ie, APACHE II score &ge;25) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/67\" class=\"abstract_t\">67</a>]. However, conflicting data from subsequent studies eventually led to a new trial, the PROWESS-SHOCK trial. In this trial, 1696 patients with vasopressor-dependent septic shock were randomly assigned to receive rhAPC or placebo [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/68\" class=\"abstract_t\">68</a>]. Preliminary analyses done by the maker of the drug indicated that rhAPC did not improve 28-day mortality (26.4 versus 24.2 percent for placebo, RR 1.09, 95% CI 0.92-1.28).</p><p>Additional therapies that have proven ineffective include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Toll-like receptor (TLR)-4 antagonist, TAK 242 (Resatorvid) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/2\" class=\"abstract_t\">2</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The human anti-endotoxin monoclonal antibody, HA-1A [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/69,70\" class=\"abstract_t\">69,70</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The human anti-Enterobacteriaceae common antigen (ECA) monoclonal antibody [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/71\" class=\"abstract_t\">71</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alkaline phosphatase [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/72\" class=\"abstract_t\">72</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulocyte colony-stimulating factor (<a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-drug-information\" class=\"drug drug_general\">filgrastim</a>, G-CSF) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/73\" class=\"abstract_t\">73</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anti-tumor necrosis factor monoclonal antibody [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/74-76\" class=\"abstract_t\">74-76</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor necrosis factor receptor antagonist [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/75,77\" class=\"abstract_t\">75,77</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interleukin-1 receptor antagonist [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/24\" class=\"abstract_t\">24</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antithrombin (formerly known as antithrombin III) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/8,78-85\" class=\"abstract_t\">8,78-85</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recombinant human tissue factor pathway inhibitor (tifacogin) [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/86,87\" class=\"abstract_t\">86,87</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">Ibuprofen</a> [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/88\" class=\"abstract_t\">88</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>N-acetylcysteine [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/89,90\" class=\"abstract_t\">89,90</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nitric oxide inhibitors [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/91-97\" class=\"abstract_t\">91-97</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The bradykinin antagonist, deltibant [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/98\" class=\"abstract_t\">98</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Growth hormone [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/99\" class=\"abstract_t\">99</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous <a href=\"topic.htm?path=selenium-drug-information\" class=\"drug drug_general\">selenium</a> supplementation [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/8,100\" class=\"abstract_t\">8,100</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Talactoferrin &ndash; restores the barrier properties of the gastrointestinal mucosa [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/101-105\" class=\"abstract_t\">101-105</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">Calcitriol</a> [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/106\" class=\"abstract_t\">106</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Levosimendan [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/107\" class=\"abstract_t\">107</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypothermia [<a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/108\" class=\"abstract_t\">108</a>]</p><p/><p class=\"headingAnchor\" id=\"H2553811\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A number of potential therapies for sepsis appear promising in animal models, but have not yet been adequately studied in humans. These include toll-like receptor antagonists and neutralizing antibodies, talactoferrin, interferon gamma, macrophage migration inhibition factor neutralizing antibody, and a synthetic peptide that inhibits bacterial superantigen-induced expression of certain proinflammatory genes. (See <a href=\"#H2\" class=\"local\">'Inhibition of innate immunity'</a> above and <a href=\"#H8\" class=\"local\">'Interferon-gamma'</a> above and <a href=\"#H11\" class=\"local\">'Augmentation of immunomodulation'</a> above and <a href=\"#H2553632\" class=\"local\">'Inhibition of proinflammatory gene expression'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other potential therapies for sepsis have been studied in humans, but have provided conflicting results and require additional investigations to clarify their effects. These include polyclonal intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG), interleukin-1 receptor antagonists, hemoperfusion through adsorptive materials or membranes, plasma exchange, whole blood exchange, coupled plasma filtration adsorption, granulocyte-macrophage colony stimulating factor (GM-CSF), hemofiltration, anticoagulants, <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a>, <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">pentoxifylline</a>, and statins. (See <a href=\"#H4\" class=\"local\">'Intravenous immune globulin'</a> above and <a href=\"#H6\" class=\"local\">'Cytokine and endotoxin inactivation or removal'</a> above and <a href=\"#H10\" class=\"local\">'Granulocyte-macrophage colony stimulating factor'</a> above and <a href=\"#H12\" class=\"local\">'Hemofiltration'</a> above and <a href=\"#H16\" class=\"local\">'Anticoagulants'</a> above and <a href=\"#H19\" class=\"local\">'Naloxone'</a> above and <a href=\"#H20\" class=\"local\">'Pentoxifylline'</a> above and <a href=\"#H21\" class=\"local\">'Statins'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential therapies that require further validation of benefit in patients with septic shock include therapy with the short-acting beta blocker, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>. (See <a href=\"#H79437663\" class=\"local\">'Beta-blockade'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential therapies for sepsis have also been investigated that were found to either cause harm or not improve clinical outcomes. (See <a href=\"#H2552815\" class=\"local\">'Ineffective therapies'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/1\" class=\"nounderline abstract_t\">Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/2\" class=\"nounderline abstract_t\">Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/3\" class=\"nounderline abstract_t\">Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007; 35:2693.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/4\" class=\"nounderline abstract_t\">Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013; :CD001090.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/5\" class=\"nounderline abstract_t\">Pildal J, G&oslash;tzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39:38.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/6\" class=\"nounderline abstract_t\">Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35:2677.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/7\" class=\"nounderline abstract_t\">Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007; 35:2686.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/8\" class=\"nounderline abstract_t\">Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45:486.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/9\" class=\"nounderline abstract_t\">Neugebauer EA. To use or not to use? Polyclonal intravenous immunoglobulins for the treatment of sepsis and septic shock. Crit Care Med 2007; 35:2855.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/10\" class=\"nounderline abstract_t\">Tagami T, Matsui H, Fushimi K, Yasunaga H. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Dis 2015; 61:385.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/11\" class=\"nounderline abstract_t\">Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23:400.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/12\" class=\"nounderline abstract_t\">Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167:412.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/13\" class=\"nounderline abstract_t\">Iwama H, Komatsu T. Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from gram-positive infection. Acta Anaesthesiol Scand 1998; 42:590.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/14\" class=\"nounderline abstract_t\">Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/15\" class=\"nounderline abstract_t\">Iwagami M, Yasunaga H, Doi K, et al. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med 2014; 42:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/16\" class=\"nounderline abstract_t\">Honore PM, Jacobs R, Joannes-Boyau O, et al. Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J 2013; 59:99.</a></li><li class=\"breakAll\">Quintel M. CytoSorb&trade; whole blood cytokine adsorption&ndash;results of a controlled randomized trial.  Presented at the 32nd International Symposium on Intensive Care and Emergency Medicine. March 20&ndash;23, 2012</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/18\" class=\"nounderline abstract_t\">Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008; 36:1573.</a></li><li class=\"breakAll\">Schadler, D., Brederlau J., Jorres, A., Marx, G., Meier-Hellmann, A., Putensen, C., Quintel, M., Spies, C., Porzelius, C., Engel, C., Weiler, N., Kuhlmann, M. Extracorporeal cytokine hemoadsorption in patients with severe sepsis and acute lung injury. Am J Respr Crit Care Med , 2013, pp.A5241</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/20\" class=\"nounderline abstract_t\">van Deuren M, Santman FW, van Dalen R, et al. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992; 15:424.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/21\" class=\"nounderline abstract_t\">Reeves JH. A review of plasma exchange in sepsis. Blood Purif 2002; 20:282.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/22\" class=\"nounderline abstract_t\">Stegmayr BG. Plasmapheresis in severe sepsis or septic shock. Blood Purif 1996; 14:94.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/23\" class=\"nounderline abstract_t\">Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 2014; 4:e003536.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/24\" class=\"nounderline abstract_t\">Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/25\" class=\"nounderline abstract_t\">Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/26\" class=\"nounderline abstract_t\">Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med 2016; 44:275.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/27\" class=\"nounderline abstract_t\">D&ouml;cke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678.</a></li><li class=\"breakAll\">Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia. http://www.clinicaltrials.gov/ct2/show/NCT01270490 (Accessed on June 12, 2011).</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/29\" class=\"nounderline abstract_t\">Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166:138.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/30\" class=\"nounderline abstract_t\">Orozco H, Arch J, Medina-Franco H, et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006; 141:150.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/31\" class=\"nounderline abstract_t\">Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/32\" class=\"nounderline abstract_t\">Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/33\" class=\"nounderline abstract_t\">Martin TR. MIF mediation of sepsis. Nat Med 2000; 6:140.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/34\" class=\"nounderline abstract_t\">Bozza FA, Gomes RN, Japiass&uacute; AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22:309.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/35\" class=\"nounderline abstract_t\">Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6:414.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/36\" class=\"nounderline abstract_t\">Borthwick EMJ, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis. Cochrane Database Syst Rev 2013; :CD008075.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/37\" class=\"nounderline abstract_t\">Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28:3581.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/38\" class=\"nounderline abstract_t\">Cornejo R, Downey P, Castro R, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006; 32:713.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/39\" class=\"nounderline abstract_t\">Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006; 32:80.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/40\" class=\"nounderline abstract_t\">Joannes-Boyau O, Honor&eacute; PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013; 39:1535.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/41\" class=\"nounderline abstract_t\">Borthwick EM, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis. Cochrane Database Syst Rev 2013; :CD008075.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/42\" class=\"nounderline abstract_t\">Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30:100.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/43\" class=\"nounderline abstract_t\">Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37:803.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/44\" class=\"nounderline abstract_t\">Zarychanski R, Doucette S, Fergusson D, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/45\" class=\"nounderline abstract_t\">Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37:1185.</a></li><li class=\"breakAll\">Safety of Heparin in Patients with Septic Shock. http://www.clinicaltrials.gov/ct2/show/NCT01234285 (Accessed on June 13, 2011).</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/47\" class=\"nounderline abstract_t\">Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13:508.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/48\" class=\"nounderline abstract_t\">Hayakawa M, Kudo D, Saito S, et al. Antithrombin Supplementation and Mortality in Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. Shock 2016; 46:623.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/49\" class=\"nounderline abstract_t\">Boeuf B, Gauvin F, Guerguerian AM, et al. Therapy of shock with naloxone: a meta-analysis. Crit Care Med 1998; 26:1910.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/50\" class=\"nounderline abstract_t\">Rock P, Silverman H, Plump D, et al. Efficacy and safety of naloxone in septic shock. Crit Care Med 1985; 13:28.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/51\" class=\"nounderline abstract_t\">Kirschenbaum LA, Aziz M, Astiz ME, et al. Influence of rheologic changes and platelet-neutrophil interactions on cell filtration in sepsis. Am J Respir Crit Care Med 2000; 161:1602.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/52\" class=\"nounderline abstract_t\">Kleinschmidt S, Wanner GA, Bussmann D, et al. Proinflammatory cytokine gene expression in whole blood from patients undergoing coronary artery bypass surgery and its modulation by pentoxifylline. Shock 1998; 9:12.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/53\" class=\"nounderline abstract_t\">Staubach KH, Schr&ouml;der J, St&uuml;ber F, et al. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998; 133:94.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/54\" class=\"nounderline abstract_t\">Papazian L, Roch A, Charles PE, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013; 310:1692.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/55\" class=\"nounderline abstract_t\">Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367:413.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/56\" class=\"nounderline abstract_t\">Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34:1080.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/57\" class=\"nounderline abstract_t\">Merx MW, Weber C. Statins: a preventive strike against sepsis in patients with cardiovascular disease? Lancet 2006; 367:372.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/58\" class=\"nounderline abstract_t\">Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333:999.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/59\" class=\"nounderline abstract_t\">Kruger PS, Harward ML, Jones MA, et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011; 183:774.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/60\" class=\"nounderline abstract_t\">Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39:1871.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/61\" class=\"nounderline abstract_t\">Thomas G, Hraiech S, Loundou A, et al. Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol 2015; 81:921.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/62\" class=\"nounderline abstract_t\">Deshpande A, Pasupuleti V, Rothberg MB. Statin therapy and mortality from sepsis: a meta-analysis of randomized trials. Am J Med 2015; 128:410.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/63\" class=\"nounderline abstract_t\">Dinglas VD, Hopkins RO, Wozniak AW, et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax 2016; 71:401.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/64\" class=\"nounderline abstract_t\">Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013; 310:1683.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/65\" class=\"nounderline abstract_t\">Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest 2017; 151:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/66\" class=\"nounderline abstract_t\">Mart&iacute;-Carvajal AJ, Sol&agrave; I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2012; :CD004388.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/67\" class=\"nounderline abstract_t\">Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699.</a></li><li class=\"breakAll\">FDA Drug Safety Communication: Voluntary Market Withdrawal of Xigris [(Drotrecogin alfa (activated)] due to failure to show a survival benefit. http://www.fda.gov/Drugs/DrugSafety/ucm277114.htm (Accessed on October 25, 2011).</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/69\" class=\"nounderline abstract_t\">McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121:1.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/70\" class=\"nounderline abstract_t\">Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000; 283:1723.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/71\" class=\"nounderline abstract_t\">Albertson TE, Panacek EA, MacArthur RD, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003; 31:419.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/72\" class=\"nounderline abstract_t\">Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37:417.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/73\" class=\"nounderline abstract_t\">Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/74\" class=\"nounderline abstract_t\">Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/75\" class=\"nounderline abstract_t\">Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/76\" class=\"nounderline abstract_t\">Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/77\" class=\"nounderline abstract_t\">Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/78\" class=\"nounderline abstract_t\">Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30:S325.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/79\" class=\"nounderline abstract_t\">Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/80\" class=\"nounderline abstract_t\">Afshari A, Wetterslev J, Brok J, M&oslash;ller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007; 335:1248.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/81\" class=\"nounderline abstract_t\">Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/82\" class=\"nounderline abstract_t\">Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34:285.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/83\" class=\"nounderline abstract_t\">Allingstrup M, Afshari A. Selenium supplementation for critically ill adults. Cochrane Database Syst Rev 2015; :CD003703.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/84\" class=\"nounderline abstract_t\">Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin&nbsp;III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2016; 42:505.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/85\" class=\"nounderline abstract_t\">Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2016; 2:CD005370.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/86\" class=\"nounderline abstract_t\">Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/87\" class=\"nounderline abstract_t\">Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/88\" class=\"nounderline abstract_t\">Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/89\" class=\"nounderline abstract_t\">Spapen HD, Diltoer MW, Nguyen DN, et al. Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest 2005; 127:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/90\" class=\"nounderline abstract_t\">Szakmany T, Hauser B, Radermacher P. N-acetylcysteine for sepsis and systemic inflammatory response in adults. Cochrane Database Syst Rev 2012; :CD006616.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/91\" class=\"nounderline abstract_t\">Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28:34.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/92\" class=\"nounderline abstract_t\">Lorente JA, Land&iacute;n L, De Pablo R, et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993; 21:1287.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/93\" class=\"nounderline abstract_t\">Avontuur JA, Boomsma F, van den Meiracker AH, et al. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation 1999; 99:271.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/94\" class=\"nounderline abstract_t\">Grover R, Zaccardelli D, Colice G, et al. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 1999; 27:913.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/95\" class=\"nounderline abstract_t\">Schoonover LL, Stewart AS, Clifton GD. Hemodynamic and cardiovascular effects of nitric oxide modulation in the therapy of septic shock. Pharmacotherapy 2000; 20:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/96\" class=\"nounderline abstract_t\">L&oacute;pez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/97\" class=\"nounderline abstract_t\">Vincent JL, Privalle CT, Singer M, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX). Crit Care Med 2015; 43:57.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/98\" class=\"nounderline abstract_t\">Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277:482.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/99\" class=\"nounderline abstract_t\">Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/100\" class=\"nounderline abstract_t\">Angstwurm MW, Engelmann L, Zimmermann T, et al. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35:118.</a></li><li class=\"breakAll\">Safety and Efficacy of Recombinant Human Lactoferrin to Treat Severe Sepsis. http://www.clinicaltrials.gov/ct2/show/NCT00630656 (Accessed on June 12, 2011).</li><li class=\"breakAll\">Talactoferrin alfa reduces mortality in severe sepsis: Results of a Phase 2 randomized, placebo-controlled, double-blind study. http://www.thoracic.org/newsroom/press-releases/resources/late-breaking-abstract-pdf/talactoferrin.pdf (Accessed on June 12, 2011).</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/103\" class=\"nounderline abstract_t\">Guntupalli KK, Dean NC, Morris PE, et al . Talactoferrin alfa reduces mortality in severe. Am J Respir Crit Care Med 2010; 181:A6768.</a></li><li class=\"breakAll\">Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis (OASIS). http://www.clinicaltrials.gov/ct2/show/NCT01273779 (Accessed on June 12, 2011).</li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/105\" class=\"nounderline abstract_t\">Vincent JL, Marshall JC, Dellinger RP, et al. Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial. Crit Care Med 2015; 43:1832.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/106\" class=\"nounderline abstract_t\">Leaf DE, Raed A, Donnino MW, et al. Randomized controlled trial of calcitriol in severe sepsis. Am J Respir Crit Care Med 2014; 190:533.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/107\" class=\"nounderline abstract_t\">Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med 2016; 375:1638.</a></li><li><a href=\"https://www.uptodate.com/contents/investigational-and-ineffective-therapies-for-sepsis/abstract/108\" class=\"nounderline abstract_t\">Itenov TS, Johansen ME, Bestle M, et al. Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. Lancet Respir Med 2018; 6:183.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1631 Version 39.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2553811\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2552507\" id=\"outline-link-H2552507\">THERAPIES BEING INVESTIGATED</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Inhibition of innate immunity</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Intravenous immune globulin</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Cytokine and endotoxin inactivation or removal</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Interferon-gamma</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Granulocyte-macrophage colony stimulating factor</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Augmentation of immunomodulation</a></li><li><a href=\"#H2553632\" id=\"outline-link-H2553632\">Inhibition of proinflammatory gene expression</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Hemofiltration</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Anticoagulants</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Naloxone</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Pentoxifylline</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Statins</a></li><li><a href=\"#H79437663\" id=\"outline-link-H79437663\">Beta-blockade</a></li><li><a href=\"#H3996667372\" id=\"outline-link-H3996667372\">Vitamin C, thiamine, and hydrocortisone combination</a></li></ul></li><li><a href=\"#H2552815\" id=\"outline-link-H2552815\">INEFFECTIVE THERAPIES</a></li><li><a href=\"#H2553811\" id=\"outline-link-H2553811\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults\" class=\"medical medical_review\">Evaluation and management of suspected sepsis and septic shock in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-intravenous-immune-globulin-ivig-therapy\" class=\"medical medical_review\">Overview of intravenous immune globulin (IVIG) therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis\" class=\"medical medical_review\">Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=statins-possible-noncardiovascular-benefits\" class=\"medical medical_review\">Statins: Possible noncardiovascular benefits</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">Treatment of hospital-acquired and ventilator-associated pneumonia in adults</a></li></ul></div></div>","javascript":null}